Serotonin transporter (SERT) inhibitors treat depression by elevating brain extracellular 5-
hydroxytryptamine (5-HT Ext). However, only one-third of patients respond adequately …

Drugs, notably SSRIs, that elevate brain extracellular 5-HT (5-HT Ext) are antidepressants.
Unfortunately, most patients fail to remit. Multipronged clinical evidence suggests that …

Depression is among the most common psychiatric disorders, and in many patients a
disorder for which available medications provide suboptimal or no symptom relief. The most …

The neurotransmitter serotonin (5-hdroxytryptamine; 5-HT) has been implicated in the
pathophysiology and treatment of major depression since the serendipitous discovery of …

The neurotransmitter serotonin is produced by neurons in the raphe nuclei of the brainstem,
which send axonal projections broadly to the cerebral cortex, the amygdala, and other brain …

hydroxytryptophan (5-HTP) has shown therapeutic promise in a range of human CNS
disorders. But native 5-HTP immediate release (IR) is poorly druggable, as rapid absorption …

Selective serotonin reuptake inhibitors (SSRIs) are a major class of antidepressants that act
by blocking inward transport of serotonin (5-HT) into presynaptic neurons mediated by the …

Despite the widespread use of antidepressant medications that block serotonin (5-
hydroxytryptamine; 5-HT) and/or norepinephrine (NE) transporters, such as SSRIs (selective …

Background: Many lines of evidence suggest the role of serotonin transporter (SERT)-
mediated reuptake of serotonin in the pathophysiology and treatment of major depressive …

First-line treatment of major depression includes administration of a selective serotonin
reuptake inhibitor (SSRI), yet studies suggest that remission rates following two trials of an …